Clinical trial
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
NCT01837797 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
- Lead sponsor
- H. Lundbeck A/S
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- April 30, 2013
- Completion date
- May 31, 2014
- Enrollment
- 129 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.